Hideki Kitahara1, Kozo Okada1, Takumi Kimura1, Paul G Yock1, Alexandra J Lansky1, Jeffrey J Popma1, Alan C Yeung1, Peter J Fitzgerald1, Yasuhiro Honda2. 1. From the Stanford University School of Medicine, CA (H.K., K.O., T.K., P.G.Y., A.C.Y., P.J.F., Y.H.); Yale University School of Medicine, New Haven, CT (A.J.L.); and Beth Israel Deaconess Medical Center, Boston, MA (J.J.P.). 2. From the Stanford University School of Medicine, CA (H.K., K.O., T.K., P.G.Y., A.C.Y., P.J.F., Y.H.); Yale University School of Medicine, New Haven, CT (A.J.L.); and Beth Israel Deaconess Medical Center, Boston, MA (J.J.P.). yshonda@stanford.edu.
Abstract
BACKGROUND: Although significant undersizing often results in incomplete stent apposition or underexpansion, the possible impact of oversized stent implantation on arterial wall injury has not been systematically investigated with drug-eluting stents. The aim of this study was to investigate the impact of stent oversizing on acute and long-term outcomes after drug-eluting stents implantation in de novo coronary lesions. METHODS AND RESULTS: Serial (baseline and 6-12 months) coronary angiography and intravascular ultrasound were performed in 2931 lesions treated with drug-eluting stents (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus). The percentage of stent oversizing to angiographic reference vessel diameter (RVD) was calculated as (nominal stent diameter-RVD)/RVD×100 (%). Clinical outcomes, including target lesion revascularization and stent thrombosis, were followed for 1 year. Overall, smaller preintervention RVD was associated with higher percentage of stent oversizing (P<0.001). The significant oversizing group underwent less post-dilatation (P=0.002) but achieved greater stent expansion (P<0.001) and less incomplete stent apposition (P<0.001) without increase of edge dissection after procedure. When stratified by vessel size and stent oversizing, progressive decreases of restenosis (P=0.002) and target lesion revascularization rates (P=0.007) were found in favor of larger vessel size and oversized stents. Stent thrombosis was observed the most in small RVD with low percentage of stent oversizing group among the subgroups (P=0.040). CONCLUSIONS: The positive impact of stent oversizing was documented on procedural and clinical outcomes. In particular, small vessels treated with smaller stents were associated with greater adverse events, suggesting that aggressive selection of larger stents, with appropriate attention to edge effects, may optimize long-term outcomes, even in drug-eluting stents implantation.
BACKGROUND: Although significant undersizing often results in incomplete stent apposition or underexpansion, the possible impact of oversized stent implantation on arterial wall injury has not been systematically investigated with drug-eluting stents. The aim of this study was to investigate the impact of stent oversizing on acute and long-term outcomes after drug-eluting stents implantation in de novo coronary lesions. METHODS AND RESULTS: Serial (baseline and 6-12 months) coronary angiography and intravascular ultrasound were performed in 2931 lesions treated with drug-eluting stents (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus). The percentage of stent oversizing to angiographic reference vessel diameter (RVD) was calculated as (nominal stent diameter-RVD)/RVD×100 (%). Clinical outcomes, including target lesion revascularization and stent thrombosis, were followed for 1 year. Overall, smaller preintervention RVD was associated with higher percentage of stent oversizing (P<0.001). The significant oversizing group underwent less post-dilatation (P=0.002) but achieved greater stent expansion (P<0.001) and less incomplete stent apposition (P<0.001) without increase of edge dissection after procedure. When stratified by vessel size and stent oversizing, progressive decreases of restenosis (P=0.002) and target lesion revascularization rates (P=0.007) were found in favor of larger vessel size and oversized stents. Stent thrombosis was observed the most in small RVD with low percentage of stent oversizing group among the subgroups (P=0.040). CONCLUSIONS: The positive impact of stent oversizing was documented on procedural and clinical outcomes. In particular, small vessels treated with smaller stents were associated with greater adverse events, suggesting that aggressive selection of larger stents, with appropriate attention to edge effects, may optimize long-term outcomes, even in drug-eluting stents implantation.
Authors: Ata Doost; James Marangou; Thato Mabote; Gerald Yong; Sharad Shetty; Alan Whelan; Matthew Erickson; Michael Nguyen; Christopher Judkins; Anthony Putrino; Abdul Rahman Ihdayhid; Richard Clugston; James Rankin Journal: AsiaIntervention Date: 2022-03-15
Authors: Suresh V Patted; Rajendra Kumar Jain; P A Jiwani; Satish Suryavanshi; T R Raghu; Hema Raveesh; S Rajalakshmi; Ashok S Thakkar; Prakash Kumar Turiya; Priyanka J Desai; Anmol Suresh Patted; Kamal H Sharma Journal: Cardiol Res Date: 2018-12-07
Authors: Florim Cuculi; Matthias Bossard; Wojciech Zasada; Federico Moccetti; Michiel Voskuil; Mathias Wolfrum; Krzysztof Piotr Malinowski; Stefan Toggweiler; Richard Kobza Journal: Open Heart Date: 2020-01-23